Product Pipeline

Product Pipeline

San Rocco Therapeutics’ strong intellectual property position is the result of acquisition and academic collaborations. The Company’s foremost objective is the rapid commercialization of its most advanced technologies. In addition, SRT continually seeks new sources of products targeting rare disorders.

The lead compound for our cell and gene therapy platform, enhanced TNS9, a treatment for the blood disorder thalassemia, is soon to enter into Phase I/II human clinical trials (2026). Our second product platform, in partnership with RCT, centers around targeting CD47 through modulation of protein expression using new generation oligonucleotide.

The following table lists the principal products being developed by the Company:

Please click on the following links for more information on SRT’s products in development: